Involvement of COX-2/PGE2 signaling in proliferation of A549 cells. by Erina Takai (465811)

“…<p>(A) A549 cells were incubated with NS-398 (50 µM) for 3 days and the cell cycle was analyzed as described in Materials and Methods. …”

Degradation of clots of different ages. by Jan Víteček (11434774)

DataSheet_1_Dectin-1 Controls TSLP-Induced Th2 Response by Regulating STAT3, STAT6, and p50-RelB Activities in Dendritic Cells.pdf by Chao Gu (402478)

“…Dectin-1 stimulation induced STAT3 activation and decreased the transcriptional activity of p50-RelB, both of which resulted in reduced OX40L expression on TSLP-activated mDCs. …”

Intracellular pH of <i>C</i>. <i>albicans</i> ATCC 90028; FLC-susceptible <i>C</i>. <i>albicans</i> D27and FLC-resistant <i>C</i>. <i>albicans</i> D15.9 with and without the treatm... by Mohammad Irfan (464459)

The process of selecting participants. by Na Li (6550)

“…Chemotherapy was found to be protective factor for OS (HR = 0.33, 95%CI: 0.30–0.37)/CSS (HR = 0.44, 95%CI: 0.39–0.50) of ovarian cancer patients, while not receiving surgery remained a risk factor. …”

C-indexes for the nomograms. by Na Li (6550)

“…Chemotherapy was found to be protective factor for OS (HR = 0.33, 95%CI: 0.30–0.37)/CSS (HR = 0.44, 95%CI: 0.39–0.50) of ovarian cancer patients, while not receiving surgery remained a risk factor. …”

The dependency of thrombolysis on rt-PA concentration. by Jan Víteček (11434774)

Axonal transport effects, APP labeling with losartan-treated vs water control. by Harry A. Quigley (695817)

Length of whole blood clots from different amounts of blood in the in vitro middle cerebral artery model (diameter 3.1 mm). by Jan Víteček (11434774)

Fixed Peripapillary Thickness. by Harry A. Quigley (695817)

Experimental study groups and the number of animals within each. by Harry A. Quigley (695817)

Primary antibodies used for histological studies and Immunoblot. by Harry A. Quigley (695817)

Blood pressure data. by Harry A. Quigley (695817)

Axial length and width. by Harry A. Quigley (695817)

Gaussian mixture model (GMM) RarA-mV by Rogelio Hernández-Tamayo (6081287)

“…RarA-mV (C-terminal mVenus fluorescent protein fusion to RarA) dynamics change from a more dynamic mode to a more static mode after induction of DNA damage (decrease of large steps and increase of small steps). …”

Multivariable model for percent axon loss. by Harry A. Quigley (695817)

Axon loss by treatment group. by Harry A. Quigley (695817)

Tonolab Calibration. by Harry A. Quigley (695817)

Results of the fitting process of the basic epidemiological model (i.e., without vaccinations). by Matthias Horn (78815)

Pressure—strain estimates in load—unload protocol for losartan and control groups. by Harry A. Quigley (695817)